| Hazard Information | Back Directory | [Uses]
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis[1]. | [in vivo]
Lirentelimab (100 μg; i.v. once) significantly inhibits IgE-mediated mast cell activation in a mice model of systemic anaphylaxis[1]. | Animal Model: | Humanized mice (NSG-SGM3) engrafts with human thymus, liver, and HSC[1] | | Dosage: | 100 μg | | Administration: | Intravenous injection; 100 μg, once | | Result: | Completely prevented passive systemic anaphylaxis (PSA) as shown by a lack of change in rectal temperature and symptom scores in mice.
|
| [References]
[1] Youngblood BA, et al. AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice. Int Arch Allergy Immunol. 2019;180(2):91-102. DOI:10.1159/000501637 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|